MAP4343
Based on 1 Customer Validation
MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 511-26-2
- Formula: C22H34O2
- Molecular Weight:330.50
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro[1].
MAP4343 (30 μM; 2-8 d) stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells[1].
MAP4343 (20 μM; 1 h) protects against microtubule depolymerization induced by Nocodazole in PC12 cells[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases MAP2 levels in spinal cord after SCI in rats[2].
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases the size of lumbar spinal motoneurons' dendrite arbours after SCI in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult Sprague-Dawley male rats with spinal cord injury[2]
-
Dosage:12 mg/kg
-
Administration:Daily s.c. for 28 days
-
Result:Increased the number of animals able to walk with weight-supported plantar steps.
Showed forelimb-hindlimb coordination at the end of the study.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 511-26-2
-
Appearance Solid
-
Molecular Weight 330.50
-
Formula C22H34O2
-
Color White to off-white
-
SMILES
C[C@@]1([C@H]2C(C)=O)[C@](CC2)([H])[C@@](CC=C(C3)[C@@]4(CC[C@@H]3OC)C)([H])[C@]4([H])CC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 25 mg/mL (75.64 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.56 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fontaine-Lenoir V, et, al. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4711-6. [Content Brief]
[2]. Duchossoy Y, et, al. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0257 mL | 15.1286 mL | 30.2572 mL | 75.6430 mL |
| 5 mM | 0.6051 mL | 3.0257 mL | 6.0514 mL | 15.1286 mL | |
| 10 mM | 0.3026 mL | 1.5129 mL | 3.0257 mL | 7.5643 mL | |
| 15 mM | 0.2017 mL | 1.0086 mL | 2.0171 mL | 5.0429 mL | |
| 20 mM | 0.1513 mL | 0.7564 mL | 1.5129 mL | 3.7821 mL | |
| 25 mM | 0.1210 mL | 0.6051 mL | 1.2103 mL | 3.0257 mL | |
| 30 mM | 0.1009 mL | 0.5043 mL | 1.0086 mL | 2.5214 mL | |
| 40 mM | 0.0756 mL | 0.3782 mL | 0.7564 mL | 1.8911 mL | |
| 50 mM | 0.0605 mL | 0.3026 mL | 0.6051 mL | 1.5129 mL | |
| 60 mM | 0.0504 mL | 0.2521 mL | 0.5043 mL | 1.2607 mL |
MAP4343 Related Classifications
HY-107116 Related Classifications
Powered by Bioz